Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). We investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
|Published (Last):||10 June 2011|
|PDF File Size:||17.91 Mb|
|ePub File Size:||16.15 Mb|
|Price:||Free* [*Free Regsitration Required]|
As well as attempting to resolve unanswered clinical issues, the setudio generated a huge epidemiological database, comprising over 20 million data items.
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Furthermore, the benefits of ukpxs reduction did not accrue for several years, unlike intensive blood pressure control. Had the separation of HbA 1c between groups been greater, a significant effect of intensive control on macrovascular disease might have been demonstrated. In addition, the few clinical trials that have been done have raised the possibility that some of the commonly used treatments may aggravate damage to large arteries.
Type 1, which usually starts in young people and always needs to be treated with insulin.
UK Prospective Diabetes Study
Data on possible dose-dependent effects of insulin, and the combination of insulin and metformin are lacking. Despite these limitations, the UKPDS provides evidence and quantitative guidelines for those in whom intensive control is achievable. Antihypertensive therapy in type 2 diabetes: Thus doctors treating the most common form of diabetes did not know how hard they and people with Type 2 diabetes should strive to keep blood glucose near-to-normal.
Improved blood-glucose control decreases the progression of diabetic microvascular disease, but the effect on macrovascular complications is unknown. Epidemiology, complications and costs of diabetes mellitus.
The study was set up so that physicians could have a sound basis for deciding which treatments they should prescribe to patients. These also demonstrated a reduction in macrovascular risk, including myocardial infarction [ 2021 ].
These results are again reassuring at first sight, but, as with the glucose control study, type 2 errors cannot be excluded; there was a trend in favour of the atenolol treated group. Serious side -effects were unusual. They were seen annually until in UKPDS clinics with continued standardized collection of endpoint, biochemical and clinical data.
UKPDS, sadly, confirmed that patients with Type 2 diabetes have a high incidence of heart attacks and strokes, and have a greater likelihood of early death than the general population.
Since medicine is the art of the feasible, a high priority could be given to ensuring good control of blood pressure. The UKPDS demonstrated that any improvement in glycaemic control and blood pressure reduces diabetes-related complications.
The predominant effect of tighter control was a reduction of microvascular disease by a quarter, largely due to a reduction in laser photocoagulation. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The rates of major hypoglycaemic episodes per year were 0. For now, until further information is available, clinical practice should be based on achieving glucose and blood pressure reduction by whatever means best suits an individual patient.
In Type 2 diabetes diabetes, the major problem is complications from large artery disease and it has not been known whether more intensive therapy would be helpful, particularly as there was concern about whether in the long term some therapies could themselves cause large vessel disease. ACE inhibitors improve survival in patients with heart failure [ 2324 ]; in type 1 diabetes, they reduce the progression of nephropathy [ 2526 ] and possibly retinopathy [ 27 ], but whether ACE inhibitors have specific advantages over other antihypertensive agents in type 2 diabetes is not yet agreed.
Whether intensive glycaemic control should be routinely introduced in type 2 diabetes is more controversial. These kinds of complications are also found in people with Type 1 diabetes. Recently the ABCD trial showed a reduction in myocardial infarction in diabetic hypertensive subjects treated with an ACE inhibitor compared with a calcium channel blocker [ 28 estuio, but it was not clear whether the ACE inhibitor was especially beneficial or the estueio channel blocker relatively harmful, particularly as the groups were inadequately matched for concomitant medication.
Overweight people could also be randomised to a tablet called metformin, as an additional option.
UK Prospective Diabetes Study : Protocol
People with diabetes usually present with thirst, weight loss and tiredness. Protocol amendments were made to add topics not originally included. In spite of insulin therapy, after a few years it can be difficult to maintain good blood glucose control.
As soon as diabetes is diagnosed, to give best chance of preventing complications. The burden of type 2 diabetes Diabetes was first recognized years ago by the Ancient Egyptians. When ikpds treatments failed, combinations were used. These showed that intensive management was neutral in its effect, with neither an adverse or beneficial effect. In the last 2 years, the results of several other studies of hypertension which have included patients with diabetes have been published.
In the meantime any way of significantly reducing the burden of diabetes-related complications will have a major impact on patient well-being and on cost effectiveness of management.
Intensive blood-glucose control by either sulphonylureas or insulin substantially decreases the risk of microvascular complications, but not macrovascular disease, in patients with type 2 diabetes. Moderately high blood glucose levels were accepted into this group. Intensive blood-glucose control with sulphonylureas or insulin ikpds with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS 33 Lancet.
It is therefore frequently called “mild diabetes”. Some of the treatments, including insulin, had the downside of giving the risk of ‘hypos’ — episodes of low blood glucose — and of greater weight gain of approximately 8 lbs 4 kg. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: